Erbitux
Author: Dominique Fontanilla
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Erbitux (cetuximab; Eli Lilly/Bristol-Myers Squibb/Merck KGaA) is a chimeric monoclonal antibody (MAb) that binds to the extracellular domain of epidermal growth factor receptor (EGFR). The receptor is involved in the regulation of cell growth, proliferation, and differentiation. Erbitux is composed of the Fv regions of a murine EGFR MAb-specific for the N-terminal portion of human EGFR with human immunoglobulin G1 heavy and k-light chain constant regions. Binding of Erbitux to EGFR interferes with ligand-mediated activation of the receptor’s intracellular tyrosine kinase activity and inhibits the EGFR-mediated signaling. This results in the inhibition of cell growth, induction of apoptosis, decreased matrix metalloprotease secretion, and reduced vascular endothelial growth factor production. Erbitux may also induce the activation of the immune system through antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity.
TABLE OF CONTENTS
4 Product Profiles
4 Erbitux : Colorectal cancer (CRC)
21 Erbitux : Head and neck cancer
LIST OF FIGURES
11 Figure 1: Erbitux for colorectal cancer – SWOT analysis
12 Figure 2: Datamonitor Healthcare’s drug assessment summary of Erbitux for colorectal cancer
13 Figure 3: Datamonitor Healthcare’s drug assessment summary of Erbitux for colorectal cancer
15 Figure 4: Erbitux sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
25 Figure 5: Erbitux for head and neck cancer – SWOT analysis
26 Figure 6: Datamonitor Healthcare’s drug assessment summary of Erbitux for SCCHN
27 Figure 7: Datamonitor Healthcare’s drug assessment summary of Erbitux for SCCHN
29 Figure 8: Erbitux sales for SCCHN across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
5 Table 1: Erbitux drug profile
6 Table 2: Overview of major approvals for Erbitux in colorectal cancer
8 Table 3: Erbitux Phase III data in colorectal cancer
10 Table 4: Erbitux Phase III data in colorectal cancer
16 Table 5: Erbitux sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
18 Table 6: Patients treated with Erbitux across the US, Japan, and five major EU markets, by country, 2016–25
22 Table 7: Erbitux drug profile
23 Table 8: Erbitux pivotal trial data in head and neck cancer
30 Table 9: Erbitux sales for SCCHN across the US, Japan, and five major EU markets, by country ($m), 2017–26
32 Table 10: Erbitux patient numbers for SCCHN across the US, Japan, and five major EU markets, by country, 2017–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the